RecruitingNCT06006819

Prognostic Markers of Acute Heart Failure With Chronic Kidney Disease

Plasma Proteomic Signature and the Prognosis of Acute Heart Failure With or Without Chronic Kidney Disease


Sponsor

Cheng-Hsin General Hospital

Enrollment

155 participants

Start Date

Jan 1, 2023

Study Type

OBSERVATIONAL

Conditions

Summary

Acute heart failure (AHF) is defined as new or worsening of symptoms and signs of heart failure and is the most frequent cause of unplanned hospital admission in elderly patients. N-terminal pro-brain natriuretic peptide (NT-pro-BNP) is one of the most developed prognostic markers for AHR patients and. NT-pro-BNP has limitations in terms of diagnostic or predictive accuracy in patients with chronic kidney disease (CKD). Plasma proteomics have the potential to examine underlying pathophysiological and prognostic roles, so we compared the plasma proteomic signature to predict outcomes of patients with or without CKD hospitalized for AHF.


Eligibility

Min Age: 20 YearsMax Age: 90 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at blood and urine markers that can predict which patients with acute heart failure and chronic kidney disease are at higher risk of poor outcomes, to help guide future treatment decisions. **You may be eligible if:** - You have been hospitalized for acute heart failure **You may NOT be eligible if:** - Your NT-proBNP level (a heart failure blood marker) is below 300 ng/mL - You are pregnant - You have had a limb amputation - You have end-stage kidney disease and are on regular dialysis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(1)

Cheng Hsin General Hospital

Taipei, Baitou District, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06006819


Related Trials